Tag:

Merck

Latest Headlines

Latest Headlines

The top 10 FierceBiotech stories of 2014

In biotech, here are the top 10 news stories of the year so far, based on web traffic.

Pfizer-Merck KGaA collaboration could benefit other oncology players with novel delivery tech

Pfizer's partnership with German counterpart Merck KGaA for $850 million upfront, plus as much as $2 billion in milestones, improves the prospects of PD-L1 and PD-1 checkpoint inhibitors in the oncology space, to the excitement of developers of combination therapies to the class of medicines, which feature both biological and mechanical mechanisms.

Merck manufacturing know-how brought to bear on NewLink Ebola vaccine

NewLink Genetics, the small Iowa company working on a promising Ebola vaccine, has been looking for manufacturing muscle, not to mention development experience and marketing know-how, to get its Ebola vaccine to market.

Merck steps into Ebola vaccine race with NewLink rights deal

Merck has snapped up the exclusive rights to NewLink Genetics' Ebola vaccine, which is being rushed into a Phase III study as part of a global effort to head off an outbreak in West Africa.

Merck in talks with NewLink to scale up Ebola vaccine production: Bloomberg

Merck may soon be the next Big Pharma to step into the Ebola vaccine arena.

UPDATED: NewLink, Merck sign Ebola vaccine licensing pact

To scale up production of its Ebola vaccine, NewLink Genetics is going to need some manufacturing help. And for that, it's turning to vaccine giant Merck.

Merck's Zetia results inflame debate over statin prescribing

How low should LDL go? That is the debate that continues among heart doctors since the American Heart Association upended statin prescribing guidelines last year, and Merck's Zetia is now in the middle of the muddle.

Ex-Merck cancer R&D chief Gilliland takes the helm at Fred Hutch

The Fred Hutchinson Cancer Research Center has tapped well-known drug investigator Gary Gilliland to become its new president.

The U.K. is open for biotech business, and Merck is buying in

The U.K. is striving to brand itself as a hotbed for biotech R&D, promising new funds for startups, pledging to speed up its approval process and courting some major players to deepen their roots in the country.

Surprise: Merck's cholesterol combo Vytorin hits goal in long-awaited outcomes trial

Merck & Co.'s cholesterol drug Vytorin hit its goal in a long-awaited outcomes trial, beating solo statin therapy at cutting cardiovascular risk. It's a vindication for the company, which endured a storm of criticism about an earlier trial in which Vytorin fell short.